Department of Radiation Oncology, Cleveland Clinic , Cleveland , OH , USA.
Department of Molecular Medicine, Cleveland Clinic , Cleveland , OH , USA.
Int J Hyperthermia. 2019;36(1):986-992. doi: 10.1080/02656736.2019.1660810.
Treatment for locally recurrent breast cancer poses a significant challenge because the benefits in local control must be weighed against the increased risk of side effects of the treatment. Frequently, patients have been heavily pre-treated with radiation and several types of chemotherapy. Moreover, they often present with large volumes of bulky disease, further complicating management. Hyperthermia can be used to improve the efficacy of radiation, particularly in the setting of recurrent disease. We reviewed our clinical and dosimetric experience of breast cancer patients who received hyperthermia and radiation for recurrent breast cancer from 2011 to 2017. Thirty-six patients were treated with hyperthermia and radiation. Median follow-up was 11 months. Thirty patients (83.3%) received prior radiotherapy. The most commonly used radiation fraction scheme was 32 Gy in 8 fractions. The median radiation dose at the time of recurrence was 35.5 Gy (range 20-64 Gy). Mild temperature hyperthermia was delivered two times per week. The median repeat radiation volume was 574 cc (range 11-3620 cc). Electrons, conventional photons, and IMRT radiation techniques were used. IMRT was used for large and complex treatment volumes and showed acceptable doses to organs at risk. The overall response rate was 61.1%. Complete response was observed in 17 patients (47.2%), partial response in 5 patients (13.9%), stable disease in 11 patients (30.6%), and progressive disease in 3 patients (8.3%). Twenty-six patients experienced acute grade 1 and 2 toxicities, primarily pain and erythema; and 26 experienced long-term grade 1 and 2 toxicities, mainly hyperpigmentation and lymphedema. Three patients developed new ulcerations that healed with conservative management. One patient developed pulmonary fibrosis resulting in mild dyspnea on exertion. Hyperthermia and radiation provide good local control with a favorable side effect profile. Thermoradiotherapy may be offered to patients with recurrent breast cancer, including those with extensive volumes of disease.
局部复发性乳腺癌的治疗是一个重大挑战,因为必须权衡局部控制的益处与治疗副作用增加的风险。通常,患者接受过大量的放疗和几种类型的化疗。此外,他们常表现为大量的大块疾病,进一步使管理复杂化。热疗可用于提高放疗的疗效,尤其是在复发性疾病的情况下。我们回顾了 2011 年至 2017 年间接受热疗和放疗治疗复发性乳腺癌的乳腺癌患者的临床和剂量学经验。36 例患者接受了热疗和放疗。中位随访时间为 11 个月。30 例(83.3%)患者接受过放疗。最常用的放疗方案为 32Gy/8f。复发时的中位放疗剂量为 35.5Gy(范围 20-64Gy)。轻度温度热疗每周进行两次。中位重复放疗体积为 574cc(范围 11-3620cc)。使用电子、常规光子和调强放疗技术。调强放疗用于大而复杂的治疗体积,对危险器官的剂量可接受。总缓解率为 61.1%。17 例患者(47.2%)观察到完全缓解,5 例患者(13.9%)观察到部分缓解,11 例患者(30.6%)病情稳定,3 例患者(8.3%)病情进展。26 例患者出现急性 1-2 级毒性,主要为疼痛和红斑;26 例患者出现长期 1-2 级毒性,主要为色素沉着和淋巴水肿。3 例患者出现新的溃疡,经保守治疗愈合。1 例患者发生肺纤维化,导致轻度运动时呼吸困难。热疗和放疗可提供良好的局部控制,副作用发生率低。热放疗法可用于复发性乳腺癌患者,包括那些有大量疾病的患者。